Duloxetine is NOT FDA-approved for panic disorder and lacks robust evidence for this indication
Duloxetine should not be routinely used for panic disorder. While duloxetine has FDA approval for generalized anxiety disorder in both adults and children ≥7 years old 1, it has no FDA indication for panic disorder. The available evidence for panic disorder consists only of one small open-label study (n=15) showing preliminary efficacy 2 and isolated case reports 3, which is insufficient to support its use.
Evidence-Based Alternatives
First-line treatment for panic disorder should be SSRIs or CBT, not duloxetine. The 2020 AACAP anxiety guidelines 4 recommend SSRIs as first-line pharmacotherapy for panic disorder in patients 6-18 years old, with combination CBT plus SSRI showing superior outcomes compared to monotherapy 4.
If an SNRI is Considered Despite Limited Evidence
If duloxetine were to be used off-label for panic disorder (which should only occur after SSRI failure or specific contraindications), the dosing would need to be extrapolated from its FDA-approved anxiety indication (GAD):
Starting dose:
- 30 mg once daily for 1 week to allow adjustment and minimize initial anxiety/agitation (a known adverse effect of SNRIs) 1
Target dose:
- 60 mg once daily after the initial week 1
- This is the evidence-based dose for GAD in adults
Maximum dose:
- Up to 120 mg once daily may be used, though there is no evidence that doses >60 mg/day confer additional benefit 1
- If escalating beyond 60 mg, increase in 30 mg increments 1
Critical Safety Considerations
Monitor for paradoxical anxiety worsening: Duloxetine can actually cause panic attacks as an adverse effect 5. One case report documented three panic attacks in two days after initiating duloxetine 30 mg/day, which resolved upon discontinuation 5.
Other important warnings 4:
- Suicidal thinking/behavior (especially age <24 years)
- Hepatotoxicity requiring discontinuation if jaundice develops
- Severe skin reactions (Stevens-Johnson syndrome)
- Sustained hypertension and increased pulse
- Discontinuation syndrome requiring slow taper
- Drug interactions via CYP1A2 and CYP2D6
Clinical Bottom Line
The appropriate approach is to use FDA-approved treatments for panic disorder (SSRIs such as sertraline, fluoxetine, or paroxetine), not duloxetine. The single small open-label study 2 and case reports 3 are insufficient to overcome the lack of FDA approval and the documented risk of duloxetine-induced panic attacks 5. If duloxetine is already being used and working, continue at 60 mg once daily, but do not initiate it as new treatment for panic disorder when superior evidence-based options exist.